Journal article
Autologous Transplantation Versus Allogeneic Transplantation in Patients With Follicular Lymphoma Experiencing Early Treatment Failure
Cancer, Vol.124(12), pp.2541-2551
06/15/2018
DOI: 10.1002/cncr.31374
PMCID: PMC5990449
PMID: 29645093
Abstract
BACKGROUND: Early treatment failure (ETF) in follicular lymphoma (FL), defined as relapse or progression within 2 years of frontline chemoimmunotherapy, is a newly recognized marker of poor survival and identifies a high-risk group of patients with an expected 5-year overall survival (OS) rate of approximately 50%. Transplantation is an established option for relapsed FL, but its efficacy in this specific ETF FL population has not been previously evaluated. METHODS: This study compared autologous hematopoietic stem cell transplantation (auto-HCT) with either matched sibling donor (MSD) or matched unrelated donor (MUD) allogeneic hematopoietic cell transplantation (allo-HCT) as the first transplantation approach for patients with ETF FL (age >= 18 years) undergoing auto-HCT or allo-HCT between 2002 and 2014. The primary endpoint was OS. The secondary endpoints were progression-free survival, relapse, and nonrelapse mortality (NRM). RESULTS: Four hundred forty FL patients had ETF (auto-HCT, 240; MSD hematopoietic stem cell transplantation [HCT], 105; and MUD HCT, 95). With a median follow-up of 69 to 73 months, the adjusted probability of 5-year OS was significantly higher after auto-HCT (70%) or MSD HCT (73%) versus MUD HCT (49%; P=.0008). The 5-year adjusted probability of NRM was significantly lower for auto-HCT (5%) versus MSD (17%) or MUD HCT (33%; P<.0001). The 5-year adjusted probability of disease relapse was lower with MSD (31%) or MUD HCT (23%) versus auto-HCT (58%; P<.0001). CONCLUSIONS: Patients with high-risk FL, as defined by ETF, undergoing auto-HCT for FL have low NRM and a promising 5-year OS rate (70%). MSD HCT has lower relapse rates than auto-HCT but similar OS. (C) 2018 American Cancer Society.
Details
- Title: Subtitle
- Autologous Transplantation Versus Allogeneic Transplantation in Patients With Follicular Lymphoma Experiencing Early Treatment Failure
- Creators
- Sonali M. Smith - University of ChicagoJames Godfrey - University of ChicagoKwang Woo Ahn - Medical College of WisconsinAlyssa DiGilio - Medical College of WisconsinSairah Ahmed - Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USAVaibhav Agrawal - Indiana UniversityVeronika Bachanova - Fairview Health ServicesUlrike Bacher - University Medical Center Hamburg-EppendorfAsad Bashey - Northside HospitalJavier Bolanos-Meade - Johns Hopkins UniversityMitchell Cairo - New York Medical CollegeAndy Chen - Oregon Health & Science UniversitySaurabh Chhabra - Medical College of WisconsinEdward Copelan - Carolinas Healthcare SystemParastoo B. Dahi - Memorial Sloan Kettering Cancer CenterMahmoud Aljurf - Alfaisal UniversityUmar Farooq - University of IowaSiddhartha Ganguly - University of KansasMark Hertzberg - Prince of Wales HospitalLeona Holmberg - Fred Hutch Cancer CenterDavid Inwards - Mayo Clinic in FloridaAbraham S. Kanate - West Virginia UniversityReem Karmali - Northwestern UniversityVaishalee P. Kenkre - University of WisconsinMohamed A. Kharfan-Dabaja - University of South FloridaAndreas Klein - Tufts UniversityHillard M. Lazarus - Case Western Reserve UniversityMatthew Mei - City Of Hope National Medical CenterAlberto Mussetti - Fondazione IRCCS Istituto Nazionale dei TumoriTaiga Nishihori - University of South FloridaPraveen Ramakrishnan Geethakumari - Thomas Jefferson UniversityAyman Saad - University of Alabama at BirminghamBipin N. Savani - Vanderbilt UniversityHarry C. Schouten - University College MaastrichtNirav Shah - Medical College of WisconsinAlvaro Urbano-Ispizua - Universitat de BarcelonaRavi Vij - Washington University in St. LouisJulie Vose - Nebraska Medical CenterAnna Sureda - Institut Català d'OncologiaMehdi Hamadani - Medical College of Wisconsin
- Resource Type
- Journal article
- Publication Details
- Cancer, Vol.124(12), pp.2541-2551
- DOI
- 10.1002/cncr.31374
- PMID
- 29645093
- PMCID
- PMC5990449
- NLM abbreviation
- Cancer
- ISSN
- 0008-543X
- eISSN
- 1097-0142
- Publisher
- Wiley
- Number of pages
- 11
- Grant note
- Swedish Orphan Biovitrum 5U10HL069294 / National Heart, Lung, and Blood Institute; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI) Actinium Pharmaceuticals, Inc Allos Therapeutics, Inc Seattle Genetics Sigma-Tau Pharmaceuticals Roswell Park Cancer Institute (Health Research, Inc) Tarix Pharmaceuticals N00014-13-1-0039; N00014-14-1-0028 / Office of Naval Research National Cancer Institute; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) Merck Co, Inc; Merck & Company Millennium: The Takeda Oncology Co. Therakos, Inc StemCyte (a Global Cord Blood Therapeutics company) Medac GmbH HistoGenetics, Inc Terumo BCT Fred Hutchinson Cancer Research Center Fresenius-Biotech North America, Inc Stemsoft Software, Inc Milliman USA, Inc St. Baldrick's Foundation Gentium SpA Osiris Therapeutics, Inc Amgen, Inc; Amgen Miltenyi Biotec, Inc Leukemia & Lymphoma Society; Leukemia and Lymphoma Society National Marrow Donor Program Medical College of Wisconsin; General Electric University of Minnesota; University of Minnesota System Blue Cross and Blue Shield Association Chimerix, Inc U24-CA076518 / National Institute of Allergy and Infectious Diseases; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID) University of Utah National Heart, Lung, and Blood Institute; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI) U10HL069294 / NATIONAL HEART, LUNG, AND BLOOD INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI) Teva Neuroscience, Inc; Teva Pharmaceutical Industries Ariad PerkinElmer, Inc Remedy Informatics WellPoint, Inc Soligenix, Inc Optum Healthcare Solutions, Inc Kiadis Pharma; Dexcel Pharma Genentech, Inc; Roche Holding; Genentech Gamida Cell Teva Joint Venture, Ltd; Teva Pharmaceutical Industries Genzyme Corporation; Sanofi-Aventis Incyte Corporation Celgene Corporation; Bristol-Myers Squibb P30CA086862; U24CA076518 / NATIONAL CANCER INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) HHSH250201200016C / Health Resources and Services Administration; United States Department of Health & Human Services; United States Health Resources & Service Administration (HRSA) Be the Match Foundation Jeff Gordon Children's Foundation Onyx Pharmaceuticals GlaxoSmithKline Otsuka America Pharmaceutical, Inc; Otsuka Pharmaceutical Sanofi US
- Language
- English
- Date published
- 06/15/2018
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984359877402771
Metrics
22 Record Views